Introduction
Cochrane reviews are primarily designed to evaluate drug therapy for treating disease. For evaluating nutrition research evidence, the Cochrane methodology, as we have seen it to date, is inadequate for the majority of nutrition questions in medical practice (Truswell, 2001a (Truswell, , b, 2002 .
Evidence-based nutrition has to be more than a Cochranetype meta-analysis of randomised controlled trials (RCTs). RCTs of diet change through to disease outcomes are uncommon and have usually involved addition or removal of only a single food component. Trials with whole diets through to disease outcome are rare and the dietary change(s) made by individuals is not the same as the prescription. Compliance is more complex than for taking a medication.
More of the evidence base in nutrition is observational, especially prospective cohort studies (though they are liable to confounding). It is hard to imagine a trial in which half (randomised) of a large group of people agree to avoid vegetables for 5 y to see their chances of developing cancer. Most of the USA's health claims, permitted by the FDA, are not supported by RCTs. There have been poor-quality nutrition RCTs-for instance, when the study is too small, when there is no objective confirmation of the experimental dietary change, or when the outcome data may be insecure. Results of controlled nutritional intervention, if well designed, should not be discarded if they are not randomised. Randomisation is not important for dietary experiments in which all participants are exposed to the same experimental diet, with control periods before and after and with multiple measurements of the variable of interest and methods closely standardised.
Two Cochrane reviews on central questions in nutrition have been disappointing and (rightly) criticised. It may be instructive to look at these in some detail.
Dietary fat intake and prevention of cardiovascular disease (CVD) in the issue of 31 March 2001. In all, 27 studies met their selection criteria, but this review has a number of flaws:
Inadequate trials
Seven trials had too few subjects, under 100 for control plus experimental subjects. In all, 12 trials were too short, lasting (on average) under 1 y. Nine trials were not designed to examine CVD. They were for women with breast conditions (three), people who were overweight (three), skin cancer (one), gallstones, colon polyps (one) and retinopathy (one). In nine trials the risk of CVD was low by the reviewers' own estimate.
Several of these trials had more than one of these limitations. In total, 17 of the 27 had too few subjects and/or too short a duration and/or were not designed to examiner CVD and/or their subjects were at low risk of CVD. Most of these 17 trials did not appear in the results of Tables 2-4 , presumably because few, if any, CVD events occurred in them.
Unsuitable cardiovascular trials
Hooper et al included the olive oil arm of a 1965 trial by Rose et al (1965) entitled 'Corn oil in treatment of ischaemic heart disease', but there was no reduction of total cholesterol in this trial although Hooper aimed to review the effect of change in dietary fat intake, which would be expected to result in a lowering of cholesterol concentration.
A more serious unsuitable inclusion was the US National Diet Heart Study (1968). This was not a trial of effect of diet on CVD outcome. It was a feasibility study. The numerous investigators at six centres had objectives like effectiveness of recruiting; availability, palatability, distribution and cost of specially prepared foods; personnel, equipment and physical facilities necessary. At several places in the 428-page report, they make it quite clear that 'The study did not and could not attempt to assess effect of diet on the disease itself' and 'The National Diet-Heart Study was a feasibility study, not a definitive mass field trial on the ability to prevent clinical episodes of coronary heart disease by dietary means. Both the number of participants and the duration of follow-up were too limited to permit acquisition of statistically significant data on comparative incidence of coronary events in the various diet groups'. There were about 10 different diet groups and the mean duration of the main trials was between 1 2 and 1 y. The dot and whisker plots for six diets from The National Diet-Heart Study in Hooper's metaanalysis figure (Figure 4) show the dots extremely low or high and the whiskers extremely wide.
Hooper et al also included one angiographic trial (STARS) with 30 patients in each group in which the outcomes on which the authors had focused was quantitative progression or regression of coronary artery narrowing (Watts et al, 1992 ).
Omission of a major trial
On the other hand, Hooper et al excluded the big Helsinki Mental Hospital Trial which was a large crossover trial in two long-stay hospitals (Turpeinen et al, 1979; Miettinen et al, 1983) . First one, then after 7 y the other hospital implemented a reduced saturated, increased polyunsaturated fat diet across the institution, while the other hospital served the standard Finnish diet of the 1960s. There were some 4736 subjects; the trial lasted 12 y, with substantial plasma cholesterol reductions in the hospital on the experimental diet. As Willet's group pointed out in a letter to the BMJ after the Hooper article, although the Finnish mental hospital study did not meet the subjective criteria, it did provide important evidence for an effect of fat modification (Hu et al, 2001) . Cochrane reviewers have been obsessed with randomisation and, in the search for this, collected trials with poor compliance and then 'combined oranges and apples in aggregating dietary studies' (Hu et al, 2001) , while they overlooked an ingeniously designed trial like Helsinki mental hospitals K and N.
Reducing total fat not expected to reduce CVD
The Seven Country Study (Keys et al, 1981) clearly showed that total fat intake is not related to the risk of coronary heart disease (CHD). 'Neither epidemiology nor clinical trials support a benefit of low fat diets on either serum cholesterol or risk of CHD' (Hu et al, 2001 ). Yet, Hooper et al mixed total fat reduction with unsaturated fats replacing saturated fats; in nine of the trials in their review, the only fat modification was reduction of total fat.
Dietary factors related to CHD are different from those related to stroke and other CVD Hooper et al set cardiovascular events as the outcome looked for following modifications of fat intake. Yet, there has never been any serious expectation that changing dietary fat does much to prevent strokes (Mann et al, 2001 ) or hypertensive diseases. There are countries with low coronary heart disease rates but high incidence of strokes, like Japan. Plasma cholesterol has not been directly linked to strokes. There has even been a report of inverse association of fat and saturated fat intake with the development of ischaemic stroke (Gillman et al, 1997) .
From the Hooper et al meta-analysis, fat modification or reduction gave relative risks of: total mortality 0.98 (not significant), cardiovascular mortality 0.91 (NS) and cardiovascular events 0.84 (significant). It does not tell us about increased unsaturated fat and CHD. The authors' final conclusions were the rather dismal statement that 'Despite decades of effort and many thousands of people randomised, there is still only limited and inconclusive evidence of the effects of modification of total, saturated, monounsaturated or polyunsaturated fats on cardiovascular morbidity and mortality' (Hooper et al, 2001 ).
Other systematic analyses
There is an earlier published meta-analysis of trials of fat modification and outcome of coronary heart disease (Truswell, 1994) . This included 14 trials, eight that appeared in Hooper et al but also included the Helsinki mental hospitals. The bottom line of this meta-analysis was, in the modified fat arm: total mortality 0.94, CHD events (fatal or not fatal) 0.87. Both these numbers were significant. Subanalyses were carried out of various selections of the trials. One interesting result was that for the eight secondary prevention trials the total mortality came down to 0.87 in the intervention group, compared with 0.96 in the primary prevention trials, reflecting the greater influence of CHD on mortality in those who already have had manifestation of CHD. The most impressive selection was in the five trials with the largest reduction of (total cholesterol Â years): total mortality was 0.89 and major CHD events 0.70 in the intervention/control groups (both numbers significant).
A more recent systematic review (Truswell, 2003 ) examines all the trials in which the only intervention was prescription of increased (o-6) polyunsaturated fat and decreased saturated fat intake. In these 10 trials, change of plasma total cholesterol ranged from À3.5 to À15%. Intervention/control CHD events ratio was 81% (significant) and total mortality 95% (NS).
Cochrane rules are designed for drug trials but for nutritional interventions useful trials should not be discarded if they are well controlled, and disease outcomes must be relevant for the dietary change.
The Hooper et al paper was evidently not accepted as a useful contribution by the many experts who collaborated in drafting the Joint WHO/FAO Expert Consultation (2003). It does not appear in the abbreviated list of 65 references in the final WHO Technical Report 916 or among the 149 references in the background paper (Reddy & Katan, 2004) . (The earlier Truswell (1994) was, however, in the longer list.) (Reddy & Katan, 2004) .
'Salt reduction in individuals. Hard to achieve, harder to sustain, and maybe not worth the effort'
This was the headline on the cover of the British Medical BMJ for 21 September 2002, which contained a Cochrane review by Lee Hooper et al, 'Systematic review of long-term effects of advice to reduce dietary salt in adults' (Hooper et al, 2002) .
In this Cochrane review, randomised trials that aimed to reduce sodium intake and lasted at least 26 weeks were collected. They had to be in adults living in the community and not multifactorial trials. Three trials in normotensive people were included, five in those with untreated hypertension and three in people being treated for hypertension. The tables and figures of the data are incomplete and difficult to read in the paper journal. Not all the 11 trials seem to have been used: only seven appear in the two metaanalysis figures and one of these shows changes in blood pressure in trials from 13 to 60 months (conflicting with the aim to collect trials at least 26 weeks long). Only four trials appear in the meta-analysis that gave the overall mean systolic blood pressure reduction of 1.12 mmHg that appears in the paper's summary. Elsewhere, in reporting results, systolic blood pressure was reduced 2.5 mm at intermediate follow-up, 1.1 mm at late follow-up. Urinary sodiums averaged 36 mmol lower in the intervention groups, but these may have been single early measurements. The authors focused on concealment of allocation, blinding of outcome assessors, but did not examine any changes of antihypertensive medication. The degree of reduction in sodium intake and blood pressure did not appear to be related in this review.
Hooper et al concluded that, 'Intensive interventions, unsuited to primary care or population prevention programmes provide only small reduction in blood pressure and sodium excretion, and effects on deaths and cardiovascular events are unclear. Advice to reduce sodium intake may help people on antihypertensive drugs to stop their medication while maintaining good pressure control'. (There was no evidence in the review to back this last sentence.)
Letters to the editor
The letters to the editor from experts on salt and blood pressure or epidemiology were very critical. MacGregor and He (2003) wrote that 75% of salt intake comes from processed foods. None of the studies reviewed provided reduced salt foods. They were particularly annoyed by the editor's nihilist interpretation, printed in large letters on the journal's cover, which conflicts with the review author's press release that rightly blames the food industry for the difficulty in reducing salt intake. Perry (2003) thought that the paper by Hooper et al adds nothing new to the literature. 'Substantial evidence accumulated over several decades shows that reducing salt intake lowers blood pressure' yy Most salt in the diet is added by the food industry to processed food such as bread, cooked meat and breakfast cereals. For Perry, the discussion section of the paper had elements of spin worthy of tabloid journalism, with selective and uncritical citation of papers, raising the spectre of possible harm from sodium restriction. (The statement was even made by Hooper et al that lowering sodium intake may have adverse effects on serum total and low density lipoprotein cholesterol!). 'Meta-analysis is a powerful tool', wrote Perry, 'but it does not absolve its practitioners from the need to exercise their critical faculties'. Law and Wald (2003) pointed out that Hooper et al did not 'satisfactorily distinguish whether salt reduction itself confers only a small benefit or a large one, but people do not materially reduce their salt intake. As a result readers may conclude from the paper that reducing salt intake is unimportant. This is not so. Reducing the current average salt consumption in Britain by 3 g/day (about one third) would reduce average blood pressure by about 5 mm Hg systolic in people over 50 and thereby reduce the incidence of heart attack and strokes by about 15 and 22% respectively yy The obstacle to prevention is that nearly all the salt we eat is hidden, added to many foods in manufacturing and processing. Only about 15% is discretionary' ..y.. Trials in which dietary advice was reinforced by the provision of low-salt staple foods, such as bread, were not included in the meta-analysis of Hooper et al. The trials in their review 'included people who had already taken steps to reduce discretionary salt, thereby diluting the effect'.
According to Beard (2004) , in his recent book, the Cochrane Collaboration's Hypertension Review Group issued a media release in January 2003, claiming that two research teams studied over 100 trials and 'available evidence does not suggest people with normal blood pressure should reduce the amount of salt in their food and drink'! This statement was picked up in medical newsletters. For Beard 'this happened because the result of a meta-analysis depends on how the authors select the trials for inclusion. The selection criteria can convert 'the ultimate gold standard' into a disastrous blunder yy Evidence based medicine is a radical advance but public health needs all the available evidence, including extensive data based on observation and inference. There are whole branches of modern science such as astronomy that depend almost exclusively on observation and inference. Observation and inference provided nearly everything we know about the cosmos -including a wealth of data used in the moon landing yy Public health is like that too'.
How subsequent expert committees saw it
The UK Scientific Advisory Committee on Nutrition (2003) report (on Salt and Health) cited Hooper et al (2002) , among many other references. They concluded, however, that 'A reduction in the average salt intake would proportionately lower population average blood pressure levels and confer significant public health benefits by contributing to a decrease in the burden of cardiovascular disease yy A reduction in the salt content of processed food and drinks is necessary. Key to this is to limit the addition of salt during processing and preparation of foods and to foods eaten outside the home'. They recommend a target reduction of the British population's average salt intake to 6 g per day, that is, 100 mmol sodium (a target first suggested for Australian public health 20 y ago (National Health & Medical Research Council, 1984) ).
Likewise, the Joint FAO/WHO Expert Consultation (2003) was convinced that sodium intake is directly associated with blood pressure. It has been studied extensively in animal experimental models, in epidemiological studies, controlled clinical trials and in population studies on restricted sodium intake. They recommend that the population goal for sodium intake should be less than 5 g NaCl/day (ie o83 mmol Na).
Conclusion
Dr Chinnock has counted for us the number of Cochrane reviews of dietary interventions and disease outcomes (about 60 now completed). These is very useful work. They need to be carefully assessed and interpreted in combination with all the other evidence (biochemical, cell culture and animal experiments, epidemiology, etc).
Cochrane reports should not be assumed to be as fully considered or carefully worded as guidelines from a committee of experts.
It was unfortunate that the two Cochrane reports I have criticised here were published in the BMJ, which has many thousands of GPs as its readers. They are busy, do not have time to read most papers in detail, but could easily have taken the headlines and summaries to mean that dietary fat change or reduced salt are both of little value. If this has the Cochrane label and was accepted by the BMJ, it is likely to be accepted as the best and latest advice. You cannot blame the editors of the BMJ, but their referees of these two papers failed in their tasks. International experts promptly wrote to point out the errors in these reviews, but an incorrect front cover has much more impact than a subsequent letter at the back of the journal. Also, the BMJ now puts most of its letters not in the printed journal but somewhere on the web site, where they are even more difficult to notice and even find.
I think the experts who wrote to the BMJ about these two unhelpful reviews would want to ask what the Cochrane organisation is doing to avoid the sort of problems I have presented.
